I
nflammatory bowel diseases (IBD) are chronic relapsing immune-mediated disorders of the intestine. IBD have become global diseases with rising incidence across every continent. 1 In North America and Europe, where the incidence of IBD is highest, the prevalence of IBD is expected to grow exponentially in the next decade because of increasing incidence of young-onset IBD combined with expansion of the aging IBD population. 2 To prepare for the growing IBD disease burden, each health care system must develop an efficient method to promptly diagnose and manage these patients. However, the diagnosis of IBD can be challenging because of a long prodromal period of nonspecific abdominal complaints that may be mistaken for the more benign irritable bowel syndrome. 3, 4 Timely diagnosis of IBD is important since early initiation of immunosuppressive/biological therapy has been shown to improve outcomes. [5] [6] [7] Studies from Europe and Asia have described variable time to IBD diagnosis from the initial symptoms ranging from 5 to 34 months in their patient population. [8] [9] [10] [11] [12] [13] The variability in time to diagnosis in these studies is likely due to regional differences in health care systems, patient characteristics, and disease behavior. The impact of diagnostic delay remains uncertain. Although some studies found a correlation between diagnostic delay and increased risk of disease complications such as intestinal surgery or strictures, [11] [12] [13] [14] [15] others did not. 10 To our knowledge, the impact of time to diagnosis in IBD has not been examined in the United States, a region with a very high IBD prevalence. 1 Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.ibdjournal.org).
The aim of this study was to investigate the impact of diagnostic delay on patient outcomes in a U.S. IBD patient cohort. We first determined the time to diagnosis of IBD in this cohort, then examined factors that may be associated with diagnostic delay and assessed the effect of diagnostic delay on patient outcomes. Finally, we explored the hypothesis that early diagnosis might positively impact on disease progression by reducing the risk of complications during follow-up.
METHODS

Study Population
This is a retrospective cohort study of patients from Carilion Clinic, a tertiary care medical center in Roanoke, Virginia. All patient data were abstracted from Carilion Clinic electronic medical records. Potential patients with IBD from July 1, 2008 to June 1, 2015 were identified using ICD-9 (555.xx, 556. xx) and ICD-10 (K50.xx, K51.xx) diagnostic codes for Crohn's disease (CD) and ulcerative colitis (UC). All patients were $16 years old and diagnosed with IBD at our institution. Diagnosis of IBD was confirmed using available clinical, endoscopic, radiologic, and pathologic information as per established guidelines. 16, 17 Patients with incomplete records at the time of initial IBD diagnosis were excluded. Other exclusion criteria included diagnosis of indeterminate colitis, IBD type unclassified, or narcotic abuse. This study was approved by Carilion Clinic Institutional Review Board.
Data Collection
We determined the time to diagnosis as the time from IBDrelated gastrointestinal symptoms to formal IBD diagnosis through independent review of the patient's medical records. To be considered forerunners of IBD, we stipulated that the gastrointestinal symptoms had to persist from the patient's initial contact with a health care provider (within our system), to the time the IBD diagnosis was established. Symptoms considered included abdominal pain, diarrhea, hematochezia, tenesmus, perianal pain or drainage, and nausea. Typically, patients sought initial medical care from primary care physicians or-less often-from emergency department (ED) physicians. Patients were then usually referred to a gastroenterologist for diagnosis and management of IBD. To assess when the potential diagnostic delay might have occurred, we further subdivided the time interval to diagnosis into: (1) the time interval from symptom onset to initial visit with a health care provider for IBD-related symptoms; (2) the time interval from symptom onset to the visit with a gastroenterologist; and (3) the time interval from symptom onset to formal IBD diagnosis.
Disease phenotype and behavior at diagnosis were classified according to the Montreal classification. 18 To assess for potential factors that may influence time to diagnosis, we collected data on patient's demographics, presenting symptoms, family history of IBD, smoking status, nonsteroidal anti-inflammatory drugs (NSAIDs) use, previous abdominal surgery, diagnosis made in the hospital, and extraintestinal manifestations (EIMs) at the time of diagnosis. EIMs included ankylosing spondylitis, aphthous stomatitis, episcleritis, erythema nodosum, peripheral arthritis, primary sclerosing cholangitis, pyoderma gangrenosum, and uveitis.
We hypothesized that IBD patients with longer time to diagnosis might present with more complicated disease at the time of diagnosis and follow-up. Data on disease complications including intestinal abscess, fistulas, perforation, strictures, perianal disease (including perianal abscess and/or fistula), and IBD-related surgery were collected. Tertiary health care utilization data-represented by the number of ED and hospital visits to our medical center for IBD-related complaints or complications-were also collected.
Statistical Analysis
All clinical data were stored in Access database. Quantitative results were portrayed as mean 6 SD or median with interquartile range (IQR). Categorical data were summarized by frequency and percentage of total. Groups with binary variables were compared using Chi-square or Fisher's exact test. Time of symptom onset to IBD diagnosis was compared using Wilcoxon rank sum test. Patients were then classified into 4 quartile groups (0-25th, 26th-50th, 51th-75th, and 76th-100th) based on the time from symptom onset to IBD diagnosis. Univariate analysis with the Cochran-Mantel-Haenszel test was performed among these 4 groups to investigate potential factors that may be associated with longer time to diagnosis. Relevant factors were further tested using a multivariable logistic regression model to evaluate association with overall complications and intestinal strictures at diagnosis. Odds ratio (OR) and 95% confidence interval (CI) were presented as the magnitude of association. For illustration purposes, the Poisson regression together with the B-spline technique was used to model the number of complications per patient as a function of time from symptoms to diagnosis. The probability of remaining stricture and surgery free after diagnosis, depending on the diagnostic delay, was estimated by the Kaplan-Meier method. Significance level was set to be 5% for all tests. All analyzes were performed using SAS 9.4 or R.
RESULTS
Patient characteristics are summarized in Table 1 . Nine hundred ten patient charts with IBD diagnosis were reviewed. Seven hundred thirty-three patients were excluded because of missing information regarding time of symptom onset to IBD diagnosis. The final cohort of 177 patients consisted of 110 patients with CD and 67 patients with UC. Patients were predominantly whites. Forty-two percent of patients were men. The average age at diagnosis for patients with CD was 38 6 17 years compared with 45 6 19 years for patients with UC (P ¼ 0.017). Fourteen percent of patients with CD had EIMs at diagnosis compared with 6% of patients with UC. Twenty-nine percent of patients with CD were smokers compared with 13% of patients with UC. Although 35% of patients with CD had at least 1 complication at diagnosis, only 1% of patients with UC had any complication at diagnosis (P , 0.001).
Time to IBD Diagnosis
The interval of time to IBD diagnosis including the interval to medical care by any physician and gastroenterologist are reported in Table 2 . Although the median time from symptom onset to initial physician visit was about 1 month for both patients with CD and UC, the median time from symptom onset to evaluation by a gastroenterologist was longer for patients with CD compared with patients with UC: approximately 7 months (IQR: 3-23) versus 3 months (IQR: 1-8), respectively (P , 0.001). The median time from symptom onset to IBD diagnosis was approximately 10 months in patients with CD (IQR: 4-26) compared with 3 months (IQR: 1-10) in patients with UC (P , 0.001). Furthermore, 25% of patients with CD were diagnosed after having experienced relevant gastrointestinal symptoms for over 26 months.
Factors That May Influence Time to Diagnosis
Patients with CD were stratified into 4 groups based on their respective quartiles of time to diagnosis (0-4, 5-10, 11-26, and .26 months). Among factors that were examined, hematochezia as the main presenting symptom was associated with a shorter time to diagnosis compared with patients without hematochezia (11.4 versus 31.0 months; P ¼ 0.046). By contrast, patients with exclusive ileal involvement had a longer time to diagnosis compared with patients without ileal involvement (37.0 versus 20.1 months; P ¼ 0.011). Age .40, sex, smoking status, NSAIDs use, family history of IBD, previous abdominal surgery, presence of EIMs, and whether the diagnosis was made during a hospital admission did not seem to be associated with delay in diagnostic time for patients with CD (Table 3) .
Patients with UC were also stratified into 4 groups based on their respective quartiles of time to diagnosis (0-1, 2-3, 4-10, and .10 months). None of the factors examined were associated with diagnostic delay in patients with UC (see Table 1 , Supplemental Digital Content 2, http://links.lww.com/IBD/B620).
Longer Time to Diagnosis in CD Is Associated with Increased Complications
IBD-related tertiary health care utilization and complications by the time of diagnosis among patients with CD were stratified by quartiles of time to diagnosis and are summarized in Table 4 . Univariate analysis showed that the average number of ED visits per patient increased with longer time to diagnosis (P ¼ 0.015). The presence of intestinal strictures, surgery, and perianal disease at the time of diagnosis correlated with longer time to diagnosis. The presence of intestinal abscess, fistulas, and perforation did not correlate with time to diagnosis. 63% of patients with CD diagnosed after 26 months of symptom onset had at least 1 complication at the time of diagnosis compared with 25% of patients diagnosed within 4 months of symptom onset.
Multivariable analysis showed increasing odds of developing any complication at the time of diagnosis in patients with longer time to diagnosis (Table 5) . Using Poisson and B-spline modeling, the number of predicted complications at diagnosis as a function of diagnostic time followed a positive rising trajectory as illustrated in Figure 1 . Patients with CD presenting with hematochezia as the main symptom were less likely to have complications at diagnosis (OR: 0.08; 95% CI, 0.01-0.83; P ¼ 0.035). Diagnosis made during a hospital admission was associated with Table 2 , Supplemental Digital Content 3, http://links.lww.com/IBD/B621). Among 72 patients without complications at diagnosis, 22.2% of those diagnosed .17 months after symptom onset (last quartile within this group) developed strictures and required surgery during follow-up. Of those patients diagnosed ,17 months after symptom onset only 1.9% and 3.7% developed strictures or required surgery, respectively. The probabilities of remaining stricture and surgery free during follow-up in these 2 groups of patients are illustrated in Figure 2A , B.
DISCUSSION
Although few studies from Europe and Asia have examined the issue of diagnostic delay in IBD, the length of diagnostic delay, contributing factors, and impact of diagnostic delay vary widely. To our knowledge, this is the first study to examine the consequence of diagnostic delay on disease outcomes in a U.S. IBD patient cohort. We found that delay in CD diagnosis was associated with increased complications at diagnosis. Furthermore, patients with CD experienced longer time to diagnosis (approximately 10 months) compared with patients with UC (3 months).
Demographics did not seem to affect the time to diagnosis. Although a higher percentage of patients with CD smoked and had a positive family history of IBD compared with UC in this study, those factors did not show a significant association with the time to diagnosis in subsequent analyses.
Initial presenting symptoms seem to be an important factor associated with the time to diagnosis. Compared with CD, patients with UC often present with hematochezia, which is alarming to health care providers and may trigger expedited work-up and referral. In this study, hematochezia was the main presenting symptom in 81% of patients with UC versus 31% of patients with CD, which may explain why patients with UC are diagnosed sooner than patients with CD. Indeed, patients with CD with hematochezia were diagnosed earlier (and had fewer complications at diagnosis), compared with those without hematochezia. Similarly, disease phenotype was associated with time to diagnosis. Patients with CD with exclusive ileal involvement were diagnosed later in time compared with those with colonic involvement. Again, a possible explanation for this finding is that patients with exclusive ileal involvement rarely present with hematochezia. Hence, the absence of this alarm symptom may have delayed work-up by health care providers.
Examination of the time interval from symptom onset to diagnosis revealed a significant delay between the time from initial primary care provider visit to final IBD diagnosis. Although both patients with CD and UC presented to their primary care provider within a month of symptom onset, it took 6 additional months for patients with CD-as opposed to 2 additional months for patients with UC-to be evaluated by a specialist. Overall, the median time to diagnosis for CD was approximately 10 months compared with 3 months in UC. A quarter of our patients with CD were not diagnosed until after 26 months of symptom onset.
Diagnostic delay may negatively impact disease outcomes. Longitudinal studies have shown that CD progresses over time from an inflammatory disease to a stricturing and/or penetrating disease. 19, 20 In this study, patients with CD with longer time to diagnosis had increased odds of developing complications and intestinal strictures at time of diagnosis in an incremental fashion. The correlation between longer time to diagnosis and increased rate of strictures and surgery persisted after diagnosis indicating that early diagnosis might impact on disease progression and clinical outcomes-likely because therapy is initiated at an earlier time. There was considerable physician-related delay, especially among primary care providers, in recognizing the disease and making appropriate referral to the specialist for evaluation. This emphasizes the need to develop an efficient diagnostic paradigm and raise awareness about the disease among primary health care providers. 21 Recently, a panel of 12 CD specialists has proposed and tested an 8-item questionnaire called the "Red Flags" index that had positive and negative likelihood ratios of 15.1 and 0.066, respectively for diagnosing CD. 22 Furthermore, a recent meta-analysis has shown that a simple office-based testing of fecal calprotectin with level ,40 mg/g was associated with #1% chance of IBD diagnosis. 23 Using a combination of fecal calprotectin and a clinical index of suspicion may be an effective method to triage patients who need expedited referral to the specialist for CD diagnosis. 24 A reduction in time to diagnosis allows for earlier treatment, which may lead to better outcomes. Indeed, several studies have demonstrated improved response to therapy and decreased adverse outcomes with early immunosuppressive therapy. [5] [6] [7] There may be additional benefits in pursuing early diagnosis in IBD such as decreased health care utilization and significant cost savings. In our study, patients with shorter time to diagnosis had a lower average number of ED visits to our medical center for IBD-related complaints before diagnosis.
A major strength of this study is that the patient cohort only included patients with IBD diagnosed at our institution. Because of the integrated nature of our electronic medical records system, documentation of the patient's initial visit to his/ her primary care provider for IBD-related symptoms and subsequent office or hospital visits (leading to the IBD diagnosis) were all included in the medical chart. This feature minimized recall biases and allowed us to easily verify subsequent health care utilization and disease complications. A unique feature of this study was the opportunity to examine in detail the impact of diagnostic delay on disease complications at the time of diagnosis before therapy initiation. Hence, we were able to observe the natural course of the untreated disease without the interference of potential confounding factors such as treatment after diagnosis.
A limitation of our study, shared by other studies, is the difficulty in distinguishing whether the patients' complaints were truly because of IBD or to concomitant irritable bowel syndrome symptoms (or other ailments) because IBD symptoms can be nonspecific. However, we determined time to diagnosis and association to disease complications based on the persistence of presenting gastrointestinal symptoms until time of IBD diagnosis. This makes it unlikely that presenting symptoms were unrelated to IBD. In addition, because this is a singlecenter retrospective study, the magnitude of the diagnostic delay, the factors associated with it, and the complications described in this patient cohort may not necessarily be generalizable to the broader population.
In conclusion, this study demonstrates significant physician-related delay in diagnosing IBD and that longer time to diagnosis was associated with an increased complication rate at diagnosis and follow-up in a U.S. patient cohort. Within our study cohort, patients with CD were diagnosed 10 months after symptom onset on average, a figure similar to that reported in a Swiss study. 14 Studies in other countries have shown a shorter 10, 15 or longer time to diagnosis 12, 13 with variations likely because of regional differences in disease behavior and patient-physician interaction within the local health care system. However, our study and others clearly show that diagnostic delay is associated with increased disease complications in IBD. [11] [12] [13] [14] [15] Future health care directives should focus on this issue and develop diagnostic paradigms for the primary care providers and specialists alike to facilitate prompt and appropriate evaluation of these patients. 
